Skip to main content
. 2020 May 14;21(10):3479. doi: 10.3390/ijms21103479

Figure 2.

Figure 2

Quality of life and primary tumours features. (A, B) Weight gain and water consumption, respectively; water consumption: p < 0.001 (***) (two-way-ANOVA and Bonferroni’s post-hoc test) was obtained comparing Micotherapy U-care (M. U-Care) treated to all other data reported. (C) Normalized value on healthy mice of total distance travelled during the 8 min of emergence test; p < 0.05 (*) (two-way-ANOVA and Bonferroni’s post-hoc test) was obtained comparing M. U-Care treated to all other data reported. *: M. U-Care treated mice at T3 vs Untreated animals at T3. §: M. U-Care treated mice at T3 vs Untreated animals at T1. #: M. U-Care treated mice at T3 vs M. U-Care treated mice at T1. (D) Primary tumour mass volume: dot plot chart showing the entire mice population (each dot represents an individual mouse); p< 0.01 (**) (unpaired Student’s t-test) was obtained comparing Untreated and M. U-Care treated groups. (E) Global quality life scoring index; NP: not performed. (F) Statistical analysis regarding global quality life scoring index: p < 0.01 (**) and p < 0.001 (***) (two-way-ANOVA and Bonferroni’s post-hoc test) were obtained comparing M. U-Care and Untreated mice concerning the following parameters: weight, water consumption, and primary tumour; NS: not significant. p < 0.05 (*) (unpaired Student’s t-test) was obtained comparing M. U-Care treated and Untreated groups concerning the following parameters: mean speed, total distance, and resting time; nc: not comparable.